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Abstract
Background: The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is
centred in North London, with over 400 cases diagnosed since 1995.
In the current study, we evaluated the genetic variation in a subset of clinical samples from the outbreak with the
hypothesis that these isolates have unique biological characteristics that have served to prolong the outbreak.
Methods: Fitness assays, mutation rate estimation, and whole-genome sequencing were performed to test for
selective advantage and compensatory mutations.
Results: This detailed analysis of the genetic variation of these INH-R samples suggests that this outbreak consists
of successful, closely related, circulating strains with heterogeneous resistance profiles and little or no associated
fitness cost or impact on their mutation rate.
Conclusions: Specific deletions and SNPs could be a peculiar feature of these INH-R M. tuberculosis isolates, and
could potentially explain their persistence over the years.
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Background
There has been a global increase in isoniazid (INH)-re-
sistant (INH-R) tuberculosis (TB) [1]. This is important
because INH resistance reduces the chance of successful
TB treatment, can lead to the development and spread
of multidrug-resistant (MDR) TB, and can reduce the ef-
fectiveness of INH preventive therapy [2]. The highest
incidence of INH resistance is in Eastern Europe, where
44.9 % of new TB cases are INH-R. This staggering pro-
portion compares to 13.9 % of all cases elsewhere [3].
The challenge of INH-R TB to public health is illus-
trated by an outbreak in London in which over 400 cases
have been diagnosed since 1995 [4]. This is the largest
reported outbreak in Western Europe. Conventional epi-
demiological analysis indicated that the patients in 50 %
of cases were born in the UK, were of white or black-
Caribbean ethnicity, and had a strong link to drug use
and prison detention. Adherence to treatment was poor
in one-third of patients and several went on to acquire
further resistance, including MDR-TB [5]. A second clin-
ically relevant feature of this outbreak is the high trans-
mission of infection to contacts (11%) compared with
other documented outbreaks (0.7–2%) [6]. This could
not be explained by the epidemiological data, suggesting
that other factors must be contributing to the extent of
this outbreak.
As previously described [7], this outbreak does not fol-
low the usual definition with a point source and serial
transmission. In fact, it is constituted by multiple clus-
ters (defined as samples related at ≥80 % similarity by
IS6110 fingerprinting and starting from a minimum of
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two cases) over a period of several years. One of the big-
gest clusters is RFL15 (from Royal Free London, and ini-
tially called Lineage 15 by Dr Robert Shorten [8]). It is this
cluster that forms the basis of our study. Demographic
characteristics from this cluster are comparable to those
from previous studies [9]. The proportion of male patients
was 54.2 % and there was no difference between the ages
of the patients in this study and those seen in the data of
Maguire [9]. The majority of our patients with TB were
black African (47.3 %), while 21.9 % were from South
Asia.
It is worth acknowledging that RFL15 only represents
a small sample of the ongoing outbreak but some of its
features make it unusual. The cluster is characterized by
persistent transmission over the years (from 2002 to
2007) and it is composed of a variety of strains with dif-
ferent antibiograms (including drug-susceptible, INH-,
and streptomycin-monoresistant as well as MDR strains
of Mycobacterium tuberculosis, MTB). Epidemiological
factors may potentially explain some of the features:
many patients in this outbreak were prisoners and drug
users residing in the North London boroughs. Even if
direct transmission could not be demonstrated, this lo-
calized prevalence does, however, indicate that strains
are circulating within specific communities.
Several reports suggest that the acquisition of resist-
ance leads to a reduction in the fitness of the affected
strain, but the full picture is far from clear [10–12]. A
spontaneous mutation that confers drug resistance should
provide an advantage in an appropriately selective envir-
onment (i.e., patient on treatment). If the mutation affects
an essential gene/function and causes a metabolic cost,
then we could reasonably hypothesize that the mutant will
be less “fit” than its sensitive precursor. However, this is
not always the case, and the use of whole-genome sequen-
cing (WGS) has confirmed the presence of compensatory
mutations that maintain a high competitive fitness [13].
Clinical strains of MTB show a genomic diversity that
varies from few single nucleotide polymorphisms (SNPs)
[14] to large-scale genomic rearrangements [15]. The
majority of deletions are considered to be present in genes
encoding for proteins not essential for the pathogenesis of
the disease, as in these analyses all strains were obtained
from clinical cases with active TB. However, some dele-
tions could conceivably result in a selective advantage at
particular stages of infection or transmission, or even en-
able escape from the host immune response. Other dele-
tions could confer a strong advantage, such as antibiotic
resistance (an example of this being deletion of the katG
gene, resulting in INH resistance [16]).
In this study we evaluated the genetic variation in a
subset of clinical samples from the London INH-R TB
outbreak with the hypothesis that these isolates have
unique biological characteristics that have served to
prolong the outbreak. A fitness assay, mutation rate estima-
tion, and WGS were performed to test the hypothesis of se-
lective advantage and compensatory mutations.
Methods
Selection of samples
As part of a previous project, MTB isolates from the
Royal Free London NHS Foundation Trust were investi-
gated between 2002 and 2007. A specific cluster (RFL15),
defined as samples related at ≥80 % similarity (by IS6110
fingerprinting), was described as part of the London INH-
R TB outbreak. All isolates available from that cluster were
evaluated by fitness assay, for mutation rate, and by WGS.
Clinical isolates were originally frozen at −80 °C and all
experiments were performed directly from the original
stock with only one passage. The reference strain MTB
H37Rv (from Public Health England, National Collection
of Type Cultures), one unrelated INH-R isolate, and two
unrelated susceptible isolates were included as controls.
Drug sensitivities were performed at the National Myco-
bacterium Reference Laboratory (Public Health England,
London, UK) as part of the routine clinical service.
Fitness assay and mutation rate
Fitness assays were performed as previously described
[17]. Automated liquid culture in the MGIT system
(MGIT960 Becton Dickinson, Oxford, UK) was used.
Mutation rate estimation was performed on 7H10 agar
plates (BD/Difco, NJ, USA) containing ciprofloxacin and
using the p0 method as previously described [18].
Extraction of DNA and whole-genome sequencing
Frozen stocks were cultured on Löwenstein-Jensen slopes
and DNA was extracted as previously described [19].
WGS was performed using the Illumina HiSeq platform
(Illumina, San Diego, CA, USA) at the Genomic Services
and Development Unit, Public Health England, according
to standard protocols. The required DNA concentration
was between 10 and 30 ng/μl with a 260/280 ratio of at
least 1.8.
Bioinformatics analysis
Sequence data were aligned to the H37Rv reference gen-
ome (RefSeq: NC_000962.3) using BWA-MEM 0.7.12
[20] and sorted using SAMtools v0.1.19 [21]. All genome
sites were called using SAMtools mpileup as described
previously [22]. The variant sites were filtered based on
the following criteria: mapping quality (MQ) of >30, site
quality score (QUAL) of >30, ≥4 reads covering each site
with ≥2 reads mapping to each strand, ≥75 % of reads
supporting the site (DP4), and an allelic frequency (AF1)
of 1. Phylogenetic reconstruction was performed using
RAxML v8.2.3 [23] with a Generalised time reversible
(GTR) model of nucleotide substitution and a Gamma
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model of rate heterogeneity; branch support values were
determined using 1000 bootstrap replicates. Branch
SNP counts were estimated by ancestral sequence re-
construction performed with PAML v4 [24]. Circular
plots were generated using Circos [25]. The Phylo-
Resistance Search Engine (PhyResSE) [26] was used to
determine lineages and clades. The full analysis pipeline
can be downloaded and run from http://github.com/
bugs-bioinf/satta-2016.
Results
Sixteen clinical isolates and three unrelated control sam-
ples were originally available, but only 13 isolates and
the controls (16 samples in total) were included in the
genetic analysis due to DNA extraction failures. Resistance
profiles are detailed in Table 1. All isolates were INH
resistant, except 02:113 and 05:046, which were fully
sensitive, and 02:302, 03:013, and 03:313, which were
streptomycin monoresistant. Samples 04.018 and 07.116
had additional resistance. Despite the different sensitivity
profiles, all isolates were included as part of RFL15
(Table 1) and for a wider comparative genetic analysis.
Fitness assay and mutation rate
The fitness and the mutation rate of the resistant isolates
were not different from either the reference strain
H37Rv, the other susceptible isolates in the cluster, or
unrelated INH-susceptible and INH-resistant samples
(Table 1).
Genetic analysis
Phylogenetic reconstruction (Fig. 1) showed that all the
clinical isolates, with the exception of 04.194, cluster to-
gether as part of RFL15. In particular, outbreak samples
02.292, 03.039, 04.018, 04.211, 04.493, 04.503 and 07.116
appear to be closely related, despite being isolated over a
period of 6 years. Samples 04.018 and 07.116 have also
developed additional resistance. Other isolates, including
05.046, 02.113 (both drug sensitive), 03.013, and 03.313
(both streptomycin monoresistant only), diverge from
Table 1 List of Mycobacterium tuberculosis clinical strains from the selected cluster RFL15
Type Isolate Lineage (clade) Resistant to Sensitive to Polymorphism for INH Relative fitness
to H37Rv
Cluster RFL15 02.113 Euro American (Cameroon) - H,R,Z,E,S None detected 0.96
02.292 Euro American (Cameroon) H R,Z,E,S inhA C→ T 0.88
02:302a Euro American S H,R,Z,E None detected 1.05
03.013 Euro American (Cameroon) S H,R,Z,E None detected 0.89
03.039 Euro American (Cameroon) H R,Z,E,S inhA C→ T 0.82
03.303a Euro American H R,Z,E,S inhA C→ T 0.92
03.313 Euro American (Cameroon) S H,R,Z,E None detected 0.98
04.018 Euro American (Cameroon) H, R, clari, ethi Z,E,S inhA C→ T 0.75
04.194 Euro American (Uganda) H R,Z,E,S katG S315T 0.96
04:198a Euro American H R,Z,E,S inhA C→ T 0.98
04.211 Euro American (Cameroon) H R,Z,E,S inhA C→ T 0.93
04.493 Euro American (Cameroon) H R,Z,E,S inhA C→ T 1.01
04.503 Euro American (Cameroon) H R,Z,E,S inhA C→ T 0.94
05.046 Euro American (Cameroon) - H,R,Z,E,S None detected 1.03
07.116 Euro American (Cameroon) H, ethi R,Z,E,S inhA C→ T 0.99
07:118 Euro American (Cameroon) H R,Z,E,S katG S315T 0.82
H-resistant control 05.177 (Control strain 1) Euro American (Uganda) H R,Z,E,S inhA C→ T 0.92
H-sensitive control 05.094 (Control strain 2) Euro American (Uganda) - H,R,Z,E,S None detected 0.88
H-sensitive control 04.011 (Control strain 3) East African Indian (Delhi/CAS) - H,R,Z,E,S katG R463L (but no
resistance)
0.81
Mutation rate - outbreak strains Mutation rate - control strains
1.3 × 10−8 × cell division 1.3 × 10−8 × cell division
ano whole-genome sequence available as unable to extract enough DNA
The first two digits in the isolate number indicate the year of isolation, for example, 02:113 was isolated in 2002. Sensitivities were based on phenotypical testing
(abbreviations: Clari clarithromycin, Ethi ethionamide, H isoniazid, R rifampicin, Z pyrazinamide, E ethambutol, S streptomycin). Only the genetic mutations
conferring isoniazid resistance are reported for simplicity. Strains in bold are closely related on further phylogenetic analysis (see phylogenetic tree)
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the main group. The control samples (05.177, 05:094,
and 04.011) are distinct as separate and independent
strains.
Deletions
Based on the phylogenetic tree results, comparative ana-
lysis for the detection of deletions was initially performed
between selected outbreak isolates (02.292, 03.039, 04.018,
04.211, 04.493, 04.503, and 07.116), the control strain
05.177 (with the same inhA mutation), and the outbreak
strain 03.313 (streptomycin monoresistant). The selected
isolates were originally chosen because they are closely
related and so would prevent further genetic variation
due to strain diversity. INH-R clinical samples demon-
strated extensive deletions in 16 genes compared with
the control strain used (05.177, still INH-R). Inclusion
of sample 03.313 reduced the deleted gene set to 13
genes (the list of genes and their functional relevance
is explained in Table 2; the BLAST ring is showed in
Fig. 2).
Single nucleotide polymorphisms
Comparative analysis was performed between the same
selected outbreak isolates (02.292, 03.039, 04.018, 04.211,
04.493, 04.503, and 07.116) and the control sample 05.177
for the detection of SNPs. A total of 563 SNPs were identi-
fied. These were compared to a recent classification of
MTB virulence factors [27], and 33 virulence genes were
identified as affected by at least one SNP (Table 3).
Insertions
Comparison between the outbreak isolate 04.211 and
the reference strain H37Rv did not revealed the presence
of any insertions (data not shown).
Discussion
Previous epidemiological studies have described the evo-
lution of INH-R strains to MDR strains via the develop-
ment of resistance to rifampicin and other drugs. It was
observed that only strains with the KatG S315T substitu-
tion were associated with successful transmission and
the development of extra resistance [28, 29]. However, in
the RFL15 cluster, inhA C-T767 is the commonest muta-
tion. In addition, the fitness and mutation rate of these
resistant isolates is not affected. This indicates that if
there were any fitness cost initially associated with the
acquisition of resistance-conferring mutations, then it was
either very small or the organisms have compensated for
it since.
The application of WGS has allowed an in-depth gen-
etic analysis of the selected outbreak isolates. At the
phylogenetic level, it is interesting to note that strain
04.194 does not seem to belong to RFL15 as previously
reported based on MIRU (Mycobacterial Interspersed
Fig. 1 Phylogenetic reconstruction of the outbreak and control strains. All clinical outbreak strains, with the exception of 04.194, cluster together
as part of RFL15. All outbreak isolates are of the Euro American (Cameroon) lineage, except sample 04.194, which is of the Euro American
(Uganda) lineage. The control strains (05.177, 05:094, and 04.011) diverge as separate and independent strains: Euro American (Uganda) for the
former two and East African Indian (Delhi) for the latter
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Repetitive Units) and RFLP (Restriction Fragment
Length Polymorphism) typing data, although it was pre-
viously considered an outlier and to be partially diver-
gent because it carries the katG mutation instead of the
inhA mutation (as sample 07.118). Also, at a deeper
lineage analysis, it belongs to clade Uganda (still a Euro-
pean American lineage), while all other outbreak sam-
ples are clade Cameroon (Table 1 and Fig. 1). This
supports the view that WGS offers a more precise means
to delineate outbreaks [19].
The outbreak isolates show genetic variation with
unique deletions and SNPs without additional insertions.
Of the 13 genes identified as deleted, most of them are
conserved hypothetical proteins and antigens whose
functions are still unknown. These can be considered
non-essential genes. Nevertheless, their deletion could
potentially offer the advantage of escape from the host
immune response and explain why these strains remain
fixed in the community, prolonging the outbreak for years.
In particular, some deletions are worth further attention
and may confirm the hypothesis of escaping/reducing the
host immune response:
– Rv1675c is a transcription factor known to be
responsive to cAMP levels, and implicated in the
biology of persistent TB infection [30]. It is a
regulator of four different protein genes (mdh,
groEL2, Rv1265, and PE_PGRS6a) during
macrophage infection by MTB and they are likely to
play a role in MTB-host interactions [31].
– the MTB genome contains four different plc genes
(plcA, plcB, plcC, and plcD) that encode for the
enzyme phospholipase C (PLC). This region
frequently contains deletions [32]. The absence/
altered function of these genes could in some way
influence the overall PLC activity, resulting in an
impaired ability to degrade the phagosome
membrane and consequent persistence of the
bacterium inside the macrophages. Alternatively, a
reduction in the release of arachidonic acid could
lead to a decreased influx of inflammatory cells to
the first site of infection, thus allowing the MTB to
partially escape an early immune response. It is
probable that PLC is involved in a number of
different mechanisms and is one part of a complex
system that allows MTB to survive inside
macrophages and sustain chronic infection [33–35].
It is difficult to interpret the real role of all 563 SNPs
identified in this study. MTB genome contains 4 million
base pairs and 3959 genes: 40 % of these have had their
function characterized, while another 44 % have been
proposed to have possible functional relevance. Musser
et al. [36] studied 24 different genes encoding target pro-
teins for the immune response of 16 different isolates of
MTB: among these, 19 genes were unvaried and just six
Table 2 List of genes with complete deletion in the isoniazid-resistant outbreak strains
Genes name (function) Isolates: 02.292, 03.039, 04.018, 04.211, 04.493, 04.503, 07.116 03.313 05.177 Control
Phirv1 phage proteins (part of genomic island) ✘ ✘ ✓
Rv1673c (conserved hypothetical protein) ✘ ✘ ✓
Rv1675c (probable cAMP and macrophage regulator) ✘ ✘ ✓
plcD (phosphoesterase) ✘ ✘ ✓
Wag22 (antigen member, PE family) ✘ ✘ ✓
Rv1760 (possible triacylglycerol synthase) ✘ ✘ ✓
Rv1761c (unknown protein) ✘ ✘ ✓
Rv1762c (unknown protein) ✘ ✘ ✓
plcB (phosphoesterase) ✘ ✓ ✓
plcA (membrane associated phospholipase) ✘ ✓ ✓
PPE54 (part of PPE family) ✘ ✓ ✓
PE_PGRS50 (antigen member, PE family) ✘ ✘ ✓
PPE55 (part of PPE family) ✘ ✘ ✓
Rv3349c (probable transposase) ✘ ✘ ✓
Rv3371 (possible triacylglycerol synthase) ✘ ✘ ✓
Rv3486 (membrane protein, function unknown) ✘ ✘ ✓
Comparison is also made with possible outbreak strain 03.313 (phylogenetically related but only streptomycin monoresistant). The symbol ✘ indicates that the
gene contains extensive deletions, while the symbol ✓indicates that the gene is still present. Deletions were found in 16 genes in the isoniazid-resistant tuberculosis
outbreak isolates compared with the control strain 05.177. Additional comparison with another possible outbreak strain (03.313) reduced the total common deletions to
13 genes. PE and PPE: proline-glutamate (PE) and proline-proline-glutamate (PPE)
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nucleotide polymorphism sites were identified in the five
genes where variation occurred. They estimated an over-
all frequency of SNPs of about 1 per 10,000 bp (around
400 SNPs for the whole genome). Later, Fraser et al. [37]
claimed a higher frequency of polymorphism (about 1 in
3000 bp) thanks to detailed comparative studies between
H37Rv and CDC1551 strains. This study took into ac-
count both synonymous and nonsynonymous nucleotide
polymorphisms, and it has to be considered that a pre-
cise evaluation of the frequency of SNPs is critical.
Several other studies seem to confirm the value of one
synonymous nucleotide change per 10,000 synonym-
ous sites in structural genes [38–40]. Considering that
the control sample 05.177 belongs to a different clade
(Uganda) from the outbreak strains (Cameroon), the
identified SNPs could reflect phylogenetic evolution
rather than specific SNPs with functional relevance.
Interestingly, mutations in 33 virulence genes were
identified: their function is summarized in Table 3.
However, only 10 of these 33 genes have a
nonsynonymous SNP. Overall, these are reported to
cause a reduction in the colony-forming unit and in
phagosome production, and increase survival, thus
allowing persistence in the human host. This further
confirms the hypothesis that these isolates have
unique biological characteristics that have served to
prolong this outbreak, granting these strains the fas-
cinating ability to persist in the host, potentially evad-
ing the immune response and allowing transmission to
contacts (as confirmed by epidemiological data).
Conclusions
Analysis of the genetic variations of INH-R TB clinical
samples from the London outbreak suggests that this
outbreak consists of successful, closely related, circulat-
ing strains with heterogeneous resistance profiles and
mutations, and little or no associated fitness cost or im-
pact on their mutation rate. Deletions and SNPs may be
a peculiar feature of these isolates and can potentially
explain the persistence of this lineage in the community
Fig. 2 BLAST ring for the graphical representation of deleted genes in the isoniazid-resistant tuberculosis outbreak. Deleted regions are shown as
white empty spaces in the alignment. The order is the same as for the phylogenetic tree. Strains 02.292, 03.039, 04.018, 04.211, 04.494, 04.503, and
07.116 (all closely related) are in red. Strains 05.046, 02.113, 03.013, and 03.313 are coloured deep blue, and control strains 05.177, 05.094, and
04.011 are light blue as H37Rv. Strain 04.194 is also shown in red
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Table 3 List of genes encoding for supposed virulence factors and affected by single nucleotide polymorphisms
Gene
name
Function Result S/NS Position Amino acid
change
ctpA Cation transporting P-type ATPase Reduced CFUs NS 100895 A/S
ctpI Cation transporting P-type ATPase Reduced CFUs S 130449 A/A
mce1F Mce protein Reduced tissue pathology and increased
survival
NS 206453 G/A
Rv0176 Mce protein Reduced CFUs, reduced tissue pathology,
and increased survival
NS 208299 P/R
pckA Iron-regulated phosphoenolpyruvate carboxykinase Reduced CFUs NS 252105 M/I
pcaA Mycolic acid cyclopropane synthase Reduced CFUs in lung NS 561021 H/Y
pstS1 phosphate-binding lipoprotein component of inorganic
phosphate transport system
Reduced multiplication NS 1042991 P/A
mprB Two component sensor kinase Reduced CFUs in lung latent stage S 1098698 G/G
oppA Oligopeptide-binding lipoprotein component of
peptide transport system
Reduced CFUs in organs in the chronic
infection, increased survival
S 1433114 G/G
oppD Oligopeptide-transport ATP binding protein Reduced CFUs in organs in the chronic
infection, increased survival
S 1434648 V/V
irtA Iron-regulated transporter Reduced CFUs in macrophages and lung S 1514732 R/R
irtB Iron-regulated transporter Reduced CFUs in macrophages and lung S 1515922 V/V
Rv1410c Aminoglycoside/tetracycline-transport integral
membrane protein
Reduced CFUs S 1586360 A/A
pks5 Polyketide synthase Reduced CFUs in organs S 1726541 Y/Y
eccB5 EsX-5 type VII secretion system protein Reduced CFUs S 2017898 T/T
eccD5 EsX-5 type VII secretion system protein Reduced CFUs S 2032701 A/A
mycP5 Pro-rich membrane-anchored serine protease (mycosin) Reduced CFUs NS 2033748 G/A
katG Catalase peroxidase peroxynitritase T Reduced CFUs, resistance to INH S 2155389 P/P
Rv1931c Probable transcriptional regulatory protein Reduced CFUs S 2183054 G/G
fadE18 Acyl-CoA dehydrogenase Reduced CFUs S 2184781 G/G
mce3A Mce protein, ? virulence factor Reduced tissue pathology and increased
survival
S 2210055 T/T
dosT Histidine kinase response regulator Moderate reduction CFUs S 2273627 G/G
pks12 Polyketide synthase Reduced CFUs S 2294876 R/R
pafA Proteasome accessory factor A Reduced CFUs in organs and less tissue
pathology
S 2355511 V/V
mpa Proteasone ATPase Reduced CFUs in organs and less tissue
pathology
S 2375883 K/K
Rv3083 Probable monooxygenase Reduced CFUs NS 3448567 H/D
nuoG NADH dehydrogenase Increased animal survival and reduced
CFUs in organs
S 3518089 G/G
Rv3236c Probable conserved integral membrane transport
protein
Reduced phagosome ROS production S 3612571 V/V
ponA2 Penicillin-binding protein Moderate reduction in CFUs NS 4122882 R/S
mmpL8 Predicted drug exporter of the RND superfamily Reduced CFUs in organs S 4291134 R/R
esxA Early secretory antigenic target Reduced CFUs S 4352875 N/N
eccE2 Type VII secretion system protein Reduced CFUs NS 4367659 V/A
eccE2 Type VII secretion system protein Reduced CFUs NS 4367911 I/T
Name of gene, function, and virulence result are shown, including if single nucleotide polymorphisms are synonymous or nonsynonymous, position, and amino
acid change (if any) (adapted from [27])
CFUs colony-forming units, NS nonsynonymous, ROS reactive oxygen species, S synonymous
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and the prolongation of the outbreak for years. Further
studies are needed to better understand the impact of
these deleted genes in the pathogenesis of TB and if any
of the virulence genes involved by SNPs can be used as
drug targets for the developement of new compounds.
Nucleotide sequence accession number
The sequence data have been deposited in the European
Nucleotide Archive with the study accession number
[PRJEB13764].
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